Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023


#226548

58pages

GlobalData

$ 3495

In Stock

 

GlobalData has released its new PharmaPoint Drug Evaluation report, Herceptin (HER2-Positive Breast Cancer) Forecast and Market Analysis to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.

 

Roche/Genentechs Herceptin (trastuzumab), first approved in the US in 1998, and in the EU in 2000, is the gold-standard treatment for HER2-positive breast cancer, and is prescribed both for patients with early-stage and metastatic disease. Herceptin is an intravenously-administered mAb that targets the HER2 receptor, blocking the downstream signaling pathways that support tumor cell survival (Genentech, 2013).

 

Scope

 

  • Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Herceptin including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Herceptin for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Herceptin performance
  • Obtain sales forecast for Herceptin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

1 Table of Contents

 

1 Table of Contents 6

1.1 List of Tables 8

1.2 List of Figures 8

 

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 10

2.3 Upcoming Related Reports 11

 

3 Disease Overview 12

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 12

3.2 Basic Breast Anatomy 14

3.3 Breast Cancer Staging 15

3.4 Prognosis 16

3.5 Quality of Life 17

3.6 Symptoms 19

 

4 Disease Management 20

4.1 Treatment Overview 20

4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 20

4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 21

4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 24

 

5 Competitive Assessment 27

5.1 Overview 27

 

6 Herceptin (trastuzumab) 29

6.1 Overview 29

6.2 Efficacy 32

6.3 Safety 34

6.4 SWOT Analysis 35

6.5 Forecast 36

 

7 Appendix 37

7.1 Bibliography 37

7.2 Abbreviations 44

7.3 Methodology 47

7.4 Forecasting Methodology 47

7.4.1 Diagnosed HER2-Positive Breast Cancer Patients 47

7.4.2 Percent Drug-Treated Patients 48

7.4.3 General Pricing Assumptions 48

7.4.4 Individual Drug Assumptions 50

7.5 Primary Research - KOLs Interviewed for this Report 53

7.6 Primary Research - Prescriber Survey 54

7.7 About the Authors 55

7.7.1 Analyst 55

7.7.2 Therapy Area Director 55

7.7.3 Global Head of Healthcare 56

7.8 About GlobalData 57

7.9 Disclaimer 57

 

Table 1: AJCC Stage Definitions for Breast Cancer 16

Table 2: Prognosis for Breast Cancer in the US 17

Table 3: Treatment Guidelines for HER2-Positive Breast Cancer 26

Table 4: Product Profile - Herceptin 31

Table 5: Clinical Studies for Herceptin in the Adjuvant Setting 33

Table 6: Herceptin SWOT Analysis, 2013 35

Table 7: Global Sales Forecast ($m) for Herceptin, 2013-2023 36

Table 8: HER2-Positive Breast Cancer Incidence, 2013-2023 48

Table 9: Average Body Weight and Surface Area Across the 8MM 49

Table 10: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant 51

Table 11: Average Annual Cost of Therapy ($) - Subcutaneous Herceptin, Adjuvant 52

Table 12: Physicians Surveyed by Country 54

 

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 14